Abingdon Health PLC (AIM:ABDX) Outcome of Judicial Review – All claims brought by GLP dismissed

York, U.K. 7 October 2022: Abingdon Health plc (AIM: ABDX), a leading international developer and manufacturer of high quality, rapid diagnostic tests, notes the judgement by Mr Justice Waksman in relation to the Judicial Review proceedings initiated by the Good Law Project Limited (“GLP”) against the Secretary of State for Health and Social Care (“DHSC”) in which Abingdon Health is an interested party.

Mr Justice Waksman has ruled in favour of the DHSC on all grounds, including lack of state aid to Abingdon Health and dismissed all claims brought by the GLP.

The judgement confirms that contract award decisions by the DHSC for the development and manufacture of lateral flow test kits for COVID-19 antibodies by Abingdon Health were lawful and complied with the principles of public law. All grounds brought by the GLP in this case were dismissed.

The monies received under these contracts totalled £10.3m (including £5.4m to cover reimbursement of stock and £0.2m in interest). This does not include a final £1.5m cash payment from the DHSC, currently held under charge until the outcome of the judicial review, that is now expected to be released, bringing the total amount paid to Abingdon by the DHSC to £11.8m (all amounts quoted exclude VAT).

Abingdon Health will release a further statement following consideration of the full judgement.


Abingdon Health plc


Chris Yates, Chief Executive Officer

Via Walbrook PR

Melanie Ross , Chief Financial Officer

Chris Hand, Non-Executive Chairman

Linking Shareholders and Executives :Share Talk

If anyone reads this article found it useful, helpful? Then please subscribe www.share-talk.com or follow SHARE TALK on our Twitter page for future updates. Terms of Website Use All information is provided on an as-is basis. Where we allow Bloggers to publish articles on our platform please note these are not our opinions or views and we have no affiliation with the companies mentioned

Weekly Newsletter

Sign up to receive exclusive stock market content in your inbox, once a week.

We don’t spam! Read our privacy policy for more info.